Free Trial

EKF Diagnostics (EKF) Competitors

GBX 30.81
+0.21 (+0.67%)
(As of 09:57 AM ET)

EKF vs. MXCT, NIOX, CREO, IUG, NCYT, BELL, IHC, AVO, RUA, and SUN

Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Belluscura (BELL), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), and Surgical Innovations Group (SUN). These companies are all part of the "medical devices" industry.

EKF Diagnostics vs.

MaxCyte (LON:MXCT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

CompanyUnderperformOutperform
MaxCyteOutperform Votes
153
68.92%
Underperform Votes
69
31.08%
EKF DiagnosticsOutperform Votes
327
76.76%
Underperform Votes
99
23.24%

EKF Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£44.05M8.78-£36.57M-£0.28-1,321.43
EKF Diagnostics£52.61M2.66£2.35M£0.013,080.60

In the previous week, EKF Diagnostics had 1 more articles in the media than MaxCyte. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for MaxCyte. EKF Diagnostics' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company Overall Sentiment
MaxCyte Neutral
EKF Diagnostics Neutral

75.0% of MaxCyte shares are owned by institutional investors. Comparatively, 71.5% of EKF Diagnostics shares are owned by institutional investors. 1.2% of MaxCyte shares are owned by insiders. Comparatively, 5.1% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

EKF Diagnostics has a net margin of 4.47% compared to EKF Diagnostics' net margin of -83.00%. MaxCyte's return on equity of 3.83% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-83.00% -15.42% -10.98%
EKF Diagnostics 4.47%3.83%3.61%

MaxCyte has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Summary

EKF Diagnostics beats MaxCyte on 11 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EKF vs. The Competition

MetricEKF DiagnosticsMedical Devices IndustryMedical SectorLON Exchange
Market Cap£139.78M£2.15B£5.27B£1.41B
Dividend Yield4.65%2.55%2.80%11.83%
P/E Ratio3,080.60235.22114.111,697.43
Price / Sales2.66243.572,108.16348,279.92
Price / Cash10.6415.8135.9232.87
Price / Book2.052.634.982.78
Net Income£2.35M£69.39M£110.49M£165.85M
7 Day Performance-3.28%0.12%2.85%62.76%
1 Month Performance8.66%2.18%9.42%64.18%
1 Year Performance6.23%38.64%5.89%20.97%

EKF Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MXCT
MaxCyte
0 of 5 stars
0.00 / 5 stars
GBX 370
-2.6%
N/A+2.7%£386.80M£44.05M-1,321.4380Gap Down
NIOX
NIOX Group
0 of 5 stars
0.00 / 5 stars
GBX 67.80
-0.6%
GBX 77
+13.6%
+6.6%£287.50M£36.80M3,390.0092
CREO
Creo Medical Group
0 of 5 stars
0.00 / 5 stars
GBX 32
-3.0%
N/A-3.6%£115.67M£30.80M-457.14279Gap Down
IUG
Intelligent Ultrasound Group
0 of 5 stars
0.00 / 5 stars
GBX 10.55
+45.5%
N/A-21.1%£34.49M£11.17M-1,055.0065News Coverage
High Trading Volume
NCYT
Novacyt
0 of 5 stars
0.00 / 5 stars
GBX 46.10
+3.9%
N/A-5.3%£32.56M£7.87M-128.06120Gap Up
BELL
Belluscura
0 of 5 stars
0.00 / 5 stars
GBX 13
-10.3%
N/A-61.8%£21.45M£1.20M-216.6724Gap Down
IHC
Inspiration Healthcare Group
0 of 5 stars
0.00 / 5 stars
GBX 18.50
+5.7%
N/A-67.6%£12.62M£41.08M-1,850.00210
AVO
Advanced Oncotherapy
0 of 5 stars
0.00 / 5 stars
GBX 1.75
-9.1%
N/AN/A£9.50MN/A-25.00174Gap Down
RUA
RUA Life Sciences
0 of 5 stars
0.00 / 5 stars
GBX 10.80
-1.8%
N/A-63.4%£6.70M£1.87M-135.0048Gap Up
SUN
Surgical Innovations Group
0 of 5 stars
0.00 / 5 stars
GBX 0.69
+6.2%
N/A-58.8%£6.44M£12.01M-21.112,300Gap Down

Related Companies and Tools

This page (LON:EKF) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners